BPG is committed to discovery and dissemination of knowledge
Featured Articles
1/21/2025 9:40:07 AM | Browse: 66 | Download: 105
 |
Received |
|
2024-07-24 12:20 |
 |
Peer-Review Started |
|
2024-07-24 12:20 |
 |
To Make the First Decision |
|
|
 |
Return for Revision |
|
2024-09-15 01:34 |
 |
Revised |
|
2024-11-10 15:23 |
 |
Second Decision |
|
2024-12-30 02:43 |
 |
Accepted by Journal Editor-in-Chief |
|
|
 |
Accepted by Executive Editor-in-Chief |
|
2024-12-30 08:38 |
 |
Articles in Press |
|
2024-12-30 08:38 |
 |
Publication Fee Transferred |
|
2024-11-18 05:14 |
 |
Edit the Manuscript by Language Editor |
|
|
 |
Typeset the Manuscript |
|
2025-01-13 03:28 |
 |
Publish the Manuscript Online |
|
2025-01-21 09:22 |
ISSN |
2218-4333 (online) |
Open Access |
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/ |
Copyright |
© The Author(s) 2024. Published by Baishideng Publishing Group Inc. All rights reserved. |
Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
Website |
http://www.wjgnet.com |
Category |
Oncology |
Manuscript Type |
Case Report |
Article Title |
Efficacy of disitamab vedotin-containing therapy in metastatic colorectal cancer: A case report
|
Manuscript Source |
Unsolicited Manuscript |
All Author List |
Hu-Cheng Yan, Yan Liu, You Feng, Jun-Ming Li, Lei-Ming Sheng, Xin Chen, Yu-Ping Xie and Na Li |
Funding Agency and Grant Number |
|
Corresponding Author |
Na Li, PhD, Department of Oncology, West China School of Public Health and West China Fourth Hospital, Sichuan University, No. 18 Section 3, Renmin South Road, Chengdu 610041, Sichuan Province, China. 281422934@qq.com |
Key Words |
Disitamab vedotin; Human epidermal growth factor receptor 2; Overexpression; Metastatic colorectal cancer; Efficacy; Case report |
Core Tip |
Colorectal cancer (CRC) is a leading cause of cancer-related mortality. In cases of metastatic CRC (mCRC) that is resistant to conventional chemotherapy, human epidermal growth factor receptor 2 (HER2)-targeted therapies have shown promise. We describe a 69-year-old woman with HER2-overexpressing mCRC, featuring an NRAS p.G12V mutation and microsatellite stability, who achieved an excellent response to disitamab vedotin treatment. This case is notable as it is the first recorded observation of a notable clinical response to anti-HER2 therapy in an mCRC patient with HER2 overexpression and an NRAS p.G12V mutation. |
Publish Date |
2025-01-21 09:22 |
Citation |
<p>Yan HC, Liu Y, Feng Y, Li JM, Sheng LM, Chen X, Xie YP, Li N. Efficacy of disitamab vedotin-containing therapy in metastatic colorectal cancer: A case report. <i>World J Clin Oncol</i> 2025; 16(3): 99527</p> |
URL |
https://www.wjgnet.com/2218-4333/full/v16/i3/99527.htm |
DOI |
https://dx.doi.org/10.5306/wjco.v16.i3.99527 |
© 2004-2025 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
California Corporate Number: 3537345